This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1352458508094399v1 14/9/1220    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Smolders, J Articles by Hupperts, R Search for Related Content PubMed PubMed Citation Articles by Smolders, J Articles by Hupperts, R Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB 1,25-DIHYDROXYCHOLECALCIFEROL Social Bookmarking                         What's this?

Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis

¹ School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands; Department of Internal Medicine, division of Clinical and Experimental Immunology, University Hospital Maastricht, Maastricht, The Netherlands
² Department of Clinical Chemistry, University Hospital Maastricht, Maastricht, The Netherlands
³ Department of Clinical Epidemiology, University Hospital Maastricht, Maastricht, The Netherlands
⁴ Department of Internal Medicine, division of Clinical and Experimental Immunology, University Hospital Maastricht, Maastricht, The Netherlands
⁵ School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands; Department of Neurology, Maaslandziekenhuis, Sittard, The Netherlands

^* To whom correspondence should be addressed.

	Abstract

Background

Multiple Sclerosis is associated with low serum levels of 25-hydroxyvitamin D (25(OH)D). We investigated the association between serum levels of 25(OH)D and 1,25-dihydroxyvitamin D (1,25(OH)2D), the biologically active metabolite, and clinical MS severity as expressed by EDSS-score and relapse rate.

Study-design

Cross-sectional study.

Patients and Methods

Serum samples from 267 MS patients were collected for 25(OH)D and 1,25(OH)2D measurement. Clinical MS parameters at the date of serum sampling were determined. Results: Both metabolite levels were significantly lower in the progressive forms compared to the relapsing remitting (RR)MS phenotype. In RRMS patients (disease course 5 years), high 25(OH)D levels were associated with a high chance of remaining relapse-free. Low 25(OH)D levels were associated with high EDSS-scores. 1,25(OH)2D was not directly associated with relapse rate or EDSS-score, and was dependent of age and 25(OH)D level.

Conclusion

Serum levels of 25(OH)D were associated with both relapse rate and disability in MS patients. These results are suggestive for a disease modulating effect of the serum concentrations of 25(OH)D on MS. The low circulating 1,25(OH)2D levels in progressive MS are due to older age and lower 25(OH)D levels. The potential consequences for vitamin D supplementation in MS will be discussed.

Key Words: 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D, multiple sclerosis, vitamin D

First published on July 24, 2008, doi:10.1177/1352458508094399

Multiple Sclerosis 2008;14:1220.

A more recent version of this article appeared on November 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. Kulie, A. Groff, J. Redmer, J. Hounshell, and S. Schrager Vitamin D: An Evidence-Based Review J Am Board Fam Med, November 1, 2009; 22(6): 698 - 706. [Abstract] [Full Text] [PDF]

				2009 ACTRIMS ABSTRACTS: Oral Presentations Multiple Sclerosis, November 1, 2009; 15(11): 1387 - 1395. [PDF]

				F. E. Nashold, K. M. Spach, J. A. Spanier, and C. E. Hayes Estrogen Controls Vitamin D3-Mediated Resistance to Experimental Autoimmune Encephalomyelitis by Controlling Vitamin D3 Metabolism and Receptor Expression J. Immunol., September 15, 2009; 183(6): 3672 - 3681. [Abstract] [Full Text] [PDF]